Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 9, 2000

View Archived Issues

Positive interim phase I/II data shown for Multikine in head and neck cancer

HumaRAD pilot clinical results reported for head and neck cancer

Cypress Bioscience expands Prosorba Column pilot program

MSI-ipratropium trial reveals efficacy of new delivery system

Insulin and sildenafil restore gastrointestinal function in diabetic mice

Suppression of mitochondrial respiration linked to osteoarthritis

Chemotherapy of head and neck cancer enhanced by gene therapy

Tamoxifen plus cisplatin improves survival in melanoma patients

CNS-reactive human MAbs promote remyelination in MS model

Genasense receives orphan drug status for treatment of malignant melanoma

MediChem-AstraZeneca collaboration extended

Phase II study of clenoliximab in rheumatoid arthritis begins

Collateral expands research collaboration with NYU

Sankyo develops rosiglitazone analogues with hypoglycemic activities

Novel growth factor receptor inhibitors described by Sugen

Prous Science selected official internet and multimedia provider for XXII ESC Congress

Pulmicort Respules approved in U.S. for children aged 1 to 8 years

New peptides under development at Ludwig Institute

Roche discloses new series of IP receptor agonists

New antiangiogenic agents under development at Merck KGaA

Nycomed Imaging describes new compounds as contrast media

MTP inhibitors under development at Janssen

New polypeptides useful for treatment of metastases

Kogenate Bayer approved in E.U. for hemophilia A

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...